Hanna Eriksson
Karolinska University Hospital(SE)Skin Cancer Foundation(US)Karolinska Institutet(SE)NU Hospital Group(SE)
Publications by Year
Research Areas
Cutaneous Melanoma Detection and Management, Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Immunotherapy and Immune Responses
Most-Cited Works
- → Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial(2019)507 cited
- → Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma(2018)360 cited
- → Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma(2021)325 cited
- → Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials(2023)116 cited
- → Tumour suppressor p16INK4a – anoikis‐favouring decrease in N/O‐glycan/cell surface sialylation by down‐regulation of enzymes in sialic acid biosynthesis in tandem in a pancreatic carcinoma model(2012)111 cited
- → Lipid-engineered Escherichia coli Membranes Reveal Critical Lipid Headgroup Size for Protein Function